A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

导出 OA

翻译打印收藏纠错

作者： Xiao,Zhang ^[1] ; Bingchun,Zhao ^[1] ; Mingmei,Ding ^[2] ; Shuo,Song ^[3] ; Yinfeng,Kang ^[4] ; Yang,Yu ^[1] ; Miao,Xu ^[1] ; Tong,Xiang ^[1] ; Ling,Gao ^[1] ; Qisheng,Feng ^[1] ; Qinjian,Zhao ^[1] ; Mu-Sheng,Zeng ^[5] ; Claude,Krummenacher ^[1] ; Yi-Xin,Zeng ^[6]

作者单位： State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China. ^[1] Present address: Vaccine Research Center, National Institute of Allergy and Infection Diseases, National Institutes of Health, Bethesda, MD, United States. ^[2] School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, PR China. ^[3] State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, China. ^[4] State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, PR China. ^[5] Department of Biological Sciences and Department of Molecular and Cellular Biosciences, Rowan University, Glassboro, NJ, United States. ^[6]

关键词 Chimeric virus-like particle Conserved epitope peptide Envelope glycoprotein Epstein-Barr virus HBc149 Neutralizing antibody.gp350